Final results from a landmark study looking at the use of GSK's Mosquirix malaria vaccine alongside antimalarial drugs and other measures have shown a 90%-plus reduction in cases. The study in ...

GSK (NYSE:GSK) has reportedly made its first shipment of its malaria vaccine Mosquirix to Africa. A shipment of 331,200 doses of Mosquirix was delivered to Cameroon on Tuesday. Prior to the ...

The RTS,S/AS01 vaccine – also known as Mosquirix – will be administered to children living in sub-Saharan Africa and other regions with moderate to high malaria transmission in what WHO ...

Next, the WHO must decide whether to recommend Mosquirix' use in vaccination programmes -- after which it will be up to national regulators to licence the drug. A child receiving malaria vaccine.

A malaria vaccine with "world-changing" potential has been developed by scientists at the University of Oxford. The team expect it to be rolled out next year after trials showed up to 80% ...

The vaccine will compete against the RTS,S shot by GSK Plc, which was recommended by the United Nations-agency in 2021 and sold under the brand Mosquirix. Malaria kills over 600,000 each year ...

Vaccines against malaria have been the object of constant endeavor by the scientific community and pharmaceutical industries for over three decades, with little success so far. Hopes for ...

Niger has become the latest West African country to roll out malaria vaccines to try to stifle the potentially deadly disease ...

The vaccine showed 49% to 57% efficacy among women who became pregnant after vaccination during a two-year trial period, providing “hope” for women who want to have a safe pregnancy from malaria.

Equity Vaccines Ltd., a pioneering subsidiary of the Equity Health Group, has set to begin clinical trials for its innovative malaria vaccine in Nigeria, marking a critical milestone in the battle ...